CLAIMS

1. An antibody-drug conjugate comprising:

a. an antigen binding protein (Ab) which binds human Tissue Factor (TF) (SEQ ID NO:810), wherein the Ab comprises three heavy chain complementarity determining regions (CDRs) (a VH-CDR1, a VH-CDR2, and a VH-CDR3) and three light chain CDRs (a VL-CDR1, a VL-CDR2, and a VL-CDR3), wherein

i. the VH-CDR1 comprises the sequence of SEQ ID NO: 872, the VH-CDR2 comprises the sequence of SEQ ID NO: 873, the VH-CDR3 comprises the sequence of SEQ ID NO: 874, the VL-CDR1 comprises the sequence of SEQ ID NO: 875, the VL-CDR2 comprises the sequence of SEQ ID NO: 876, and the VL-CDR3 comprises the sequence of SEQ ID NO: 877,

ii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25A3,

iii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25A,

iv. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25A5,

v. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25A5-T, or

vi. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25G1;

and

b. one or more linker-toxin moieties represented by Formula IV:



Formula IV

wherein:

X is *-C(O)NHCH($CH_2(R^2)$)-$^{+}$, wherein * and + represent the respective points of attachment as indicated in Formula IV, or X is absent;

L is a linker;

! represents the point of attachment of L to the Ab, where L is attached to the Ab through a covalent bond;

R^1 is selected from the group consisting of:



, and ,

wherein # and % represent the respective points of attachment as indicated in Formula IV; and

R^2 is phenyl.

2. The antibody-drug conjugate of claim 1, wherein:

(i) L is a cleavable linker, and/or L is a peptide-containing linker; or

L is a linker selected from one of N-(β-maleimidopropyloxy)-N-hydroxy succinimide ester (BMPS), N-(ε-maleimidocaproyloxy) succinimide ester (EMCS), N-[γ-maleimidobutyryloxy]succinimide ester (GMBS), 1,6-hexane-bis-vinylsulfone (HBVS), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate) (LC-SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-Maleimidophenyl)butyric acid hydrazide (MPBH), succinimidyl 3-(bromoacetamido)propionate (SBAP), succinimidyl iodoacetate (SIA), succinimidyl (4-iodoacetyl)aminobenzoate (SIAB), N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), succinimidyl 6-[(β-maleimidopropionamido)hexanoate] (SMPH), iminothiolane (IT), sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-

SIAB, sulfo-SMCC, sulfo-SMPB, and succinimidyl-(4-vinylsulfone)benzoate (SVSB); and/or

(ii) L comprises a poly(ethylene)glycol chain of the formula:



wherein g is an integer from 1-20.

3. The antibody-drug conjugate of claim 1, wherein L is represented by Formula VII:



Formula VII

wherein:

Z represents a functional group that binds to a target group of the Ab;

D represents the point of attachment to the amino group as indicated in Formula IV;

Str is a stretcher;

AA_1 and AA_2 are each independently an amino acid, wherein AA_1-$[AA_2]_m$ forms a protease cleavage site;

X_1 is a self-immolative group;

s is an integer selected from 1 and 0;

m is an integer selected from the group consisting of 1, 2, 3, and 4;

o is an integer selected from 0, 1, and 2,

optionally wherein the one or more linker-toxin moieties represented by Formula IV are 1, 2, 3, 4 or 5 linker-toxin moieties represented by Formula IV,

optionally wherein:

$[Str]_s$ is selected from the group consisting of alkylene, stretchers based on aliphatic acids, stretchers based on aliphatic diacids, stretchers based on aliphatic amines and stretchers based on aliphatic diamines; and/or

$[Str]_s$ is selected from the group consisting of diglycolate-based stretchers, malonate-based stretchers, caproate-based stretchers and caproamide-based stretchers;

and/or

$[Str]_s$ is selected from the group consisting of glycine-based stretchers, polyethylene glycol-based stretchers, and monomethoxy polyethylene glycol-based stretchers;

and/or

$[Str]_s$ is:



wherein

h is an integer from 1-20,

CC refers to the point of attachment to AA_1; and

DD refers to the point of attachment to Z;

or

$[Str]_s$ is selected from the group consisting of:



,


,


,



,


, and



;

wherein:

EE and FF represent the points of attachment to Z and AA_1, respectively;
R is selected from hydrogen and C_1-C_6 alkyl;
each occurrence of p is independently an integer from 2 to 10; and
each occurrence of q is independently an integer from 1 to 10;

and/or
$[Str]_s$ is selected from the group consisting of:



,


, and


,

wherein:
EE and FF represent the points of attachment to Z and AA_1, respectively;
each occurrence of p is independently an integer from 2 to 10; and
each occurrence of q is independently an integer from 1 to 10;

and/or

$[Str]_s$ is selected from the group consisting of:



and


,

wherein:
EE and FF represent the points of attachment to Z and AA_1, respectively;
each occurrence of p is independently an integer from 2 to 6, and
q is an integer from 2 to 8.

4. The antibody-drug conjugate of claim 3, wherein:

AA_1-$[AA_2]_m$ is selected from Val-Lys, Ala-Lys, Phe-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit, Trp-Cit, Phe-Arg, Ala-Phe, Val-Ala, Met-Lys, Asn-Lys, Ile-Pro, Ile-Val, Asp-Val, His-Val, Met-(D)Lys, Asn-(D)Lys, Val-(D)Asp, NorVal-(D)Asp, Ala-(D)Asp, Me_3Lys-Pro, PhenylGly-(D)Lys, Met-(D)Lys, Asn-(D)Lys, Pro-(D)Lys, Met-(D)Lys, Met-Cit-Val, Gly-

Cit-Val, (D)Phe-Phe-Lys, (D)Ala-Phe-Lys, Gly-Phe-Leu-Gly (SEQ ID NO: 922), and Ala-Leu-Ala-Leu (SEQ ID NO: 923); and/or

m is selected from 1, 2, and 3; and/or

AA_1-$[AA_2]_m$ is a dipeptide selected from Val-Lys, Ala-Lys, Phe-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit and Trp-Cit; and/or

each X_1 is independently selected from p-aminobenzyloxycarbonyl (PABC), p-aminobenzyl ether (PABE) and methylated ethylene diamine (MED); and/or

s is 1, and optionally h is 3; and/or

o is 0.

5. The antibody drug-conjugate of claim 1, wherein:

the linker-toxin moiety is of the Formula VIII:



Formula VIII

wherein ## represents the point of attachment of the linker-toxin moiety to the Ab through a covalent bond; or

the linker L is:

as represented by Formula X:



Formula X

wherein:

is the point of attachment to the Ab and the succinimidyl group is attached to the Ab through a covalent bond;

Y is one or more additional linker components, or is absent; and

D_1 is the point of attachment to the toxin;

or

as represented by Formula XI:



Formula XI

wherein:

is the point of attachment to the Ab and the succinimidyl group is attached to the Ab through a covalent bond;

Y is one or more additional linker components, or is absent; and

D_1 is the point of attachment to the toxin.

6. The antibody-drug conjugate of any one of claims 1-5, wherein the Ab comprises:

a. a variable heavy (VH) sequence shown in SEQ ID NO: 868 and a variable light (VL) sequence shown in SEQ ID NO: 869,

b. a VH sequence shown in SEQ ID NO: 151 and a VL sequence shown in SEQ ID NO: 152,

c. a VH sequence shown in SEQ ID NO: 113 and a VL sequence shown in SEQ ID NO: 114,

d. a VH sequence shown in SEQ ID NO: 189 and a VL sequence shown in SEQ ID NO: 190,

e. a VH sequence shown in SEQ ID NO: 836 and a VL sequence shown in SEQ ID NO: 837, or

f. a VH sequence shown in SEQ ID NO: 265 and a VL sequence shown in SEQ ID NO: 266.

7. The antibody-drug conjugate of any one of claims 1-6, wherein the Ab comprises:

a. a heavy chain sequence comprising QVQLVQSGAEVKKPGASVKVSCKASGYTFDx[V/A]YGISWVRQAPGQ GLEWMGWIAPYx[N/S]GNTNYAQKLQGRVTMTTDTSTSTAYMELRSL RSDDTAVYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVF PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 924) and a light chain sequence comprising DIQMTQSPSTLSASVGDRVTITCx[R/Q]ASx[Q/E]SIx[S/N]x[S/N]WLAW YQQKPGKAPKLLIYKAx[S/Y]x[S/N]LEx[S/Y]GVPSRFSGSGSGTEFTLTI SSLQPDDFATYYCQx[Q/L]FQx[S/K]LPPFTFGGGTKVEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG EC (SEQ ID NO: 942),

b. a heavy chain sequence comprising QVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQAPGQGLE WMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTA VYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 926) and a light chain sequence comprising
DIQMTQSPSTLSASVGDRVTITCQASQSINNWLAWYQQKPGKAPKLLI
YKAYNLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQLFQSLPPFT
FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
CEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 927),

c. a heavy chain sequence comprisingQVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQA
PGQGLEWMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSL
RSDDTAVYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVF
PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 926) and a light chain sequence comprising
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIY
KASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQFQSLPPFTF
GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 928),

d. a heavy chain sequence comprisingQVQLVQSGAEVKKPGASVKVSCKASGYTFDAYGISWVRQA
PGQGLEWMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSL
RSDDTAVYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVF
PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP

EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 929)
and a light chain sequence comprising
DIQMTQSPSTLSASVGDRVTITCRASESISNWLAWYQQKPGKAPKLLIY
KAYSLEYGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQFQKLPPFTF
GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 930),

e. a heavy chain sequence
comprisingQVQLVQSGAEVKKPGASVKVSCKASGYTFRSYGISWVRQA
PGQGLEWMGWVAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSL
RSDDTAVYYCARDAGTYSPYGYGMDVWGQGTTVTVSSASTKGPSVF
PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK
THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 931)
and a light chain sequence comprising
DIQMTQSPSTLSASVGDRVTITCRASHSIDSWLAWYQQKPGKAPKLLI
YKASYLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQLFQSLPPFT
FGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
CEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 932), or

f. a heavy chain sequence
comprisingQVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQA
PGQGLEWMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSL
RSDDTAVYYCARDAGTYSPFGYGMDVWGQGTTVTVSSASTKGPSVF
PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK

THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 926)
and a light chain sequence comprising
DIQMTQSPSTLSASVGDRVTITCRASESISNWLAWYQQKPGKAPKLLIY
KAYSLEYGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQFQKLPPFTF
GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ
WKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC
EVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 930).

8. The antibody-drug conjugate of claim 1, wherein the antibody-drug conjugate has Formula IX:



Formula IX

wherein:

the Ab comprises a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the Ab designated 25A3, and

n is an integer greater than or equal to 1, optionally wherein n is selected from the group consisting of 1, 2, 3, 4, and 5;

optionally wherein

the Ab comprises a variable heavy (VH) sequence shown in SEQ ID NO: 151 and a variable light (VL) sequence shown in SEQ ID NO: 152; and/or

the Ab comprises a heavy chain sequence comprising QVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQAPGQGLEWMGWIAPYS GNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDAGTYSPFGYGM DVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP G (SEQ ID NO: 926) and a light chain sequence comprising DIQMTQSPSTLSASVGDRVTITCQASQSINNWLAWYQQKPGKAPKLLIYKAYNLESG VPSRFSGSGSGTEFTLTISSLQPDDFATYYCQLFQSLPPFTFGGGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 927).

9. The antibody-drug conjugate of any one of claims 1-8, wherein:

the Ab is multispecific; and/or

the Ab comprises a Fab, Fab', $F(ab')_2$, Fv, scFv, $(scFv)_2$, single chain antibody molecule, dual variable domain antibody, single variable domain antibody, linear antibody, or V domain antibody; and/or

the Ab comprises a scaffold, optionally wherein the scaffold is Fc, optionally human Fc, optionally wherein the Fc comprises one or more modifications, wherein the one or more modifications result in increased half-life, increased antibody-dependent cellular cytotoxicity (ADCC), increased antibody-dependent cellular phagocytosis (ADCP), increased complement-dependent cytotoxicity (CDC), or decreased effector function, compared with the Fc without the one or more modifications; and/or

the Ab comprises a heavy chain constant region of a class selected from IgG, IgA, IgD, IgE, and IgM, optionally wherein the Ab comprises a heavy chain constant region of the class IgG, wherein the heavy chain constant region is from a subclass selected from IgG1, IgG2, IgG3, and IgG4.

10. The antibody-drug conjugate of any one of claims 1-9, wherein, upon administration to a tumor-bearing subject, the antibody-drug conjugate is able to reduce tumor volume or inhibit tumor growth in the subject; and/or

the antibody-drug conjugate is able to reduce tumor volume or tumor growth in a tumor-bearing subject by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%; and/or

the antibody-drug conjugate does not result in measurable skin toxicity or results in reduced skin toxicity relative to a different anti-TF antibody-drug conjugate (ADC); and/or

administration of the antibody-drug conjugate does not require administration of one or more anti-inflammatory agents, or results in a reduced need for one or more anti-inflammatory agents relative to a different anti-TF ADC, optionally wherein the one or more anti-inflammatory agents comprises at least one of topical steroids and systemic steroids; and/or

the antibody-drug conjugate results in reduced or absent neutropenia in the subject relative to baseline levels or does not alter, increase or decrease the number of monocytes in the subject relative to baseline levels.

11. A pharmaceutical composition comprising the antibody-drug conjugate of any one of claims 1-10 and a pharmaceutically acceptable carrier.

12. The pharmaceutical composition of claim 11, wherein the composition comprises a multiplicity of drug-antibody ratio (DAR) species, wherein the average DAR of the composition is 2-4.

13. Use of the antibody-drug conjugate of any one of claims 0-10 or the pharmaceutical composition of claim 11 or 12, in the manufacture of a medicament for treating or preventing a disease or condition in a subject in need thereof, optionally a human subject, optionally wherein

the treating or preventing is treating or delaying the onset of cancer in a subject in need thereof, optionally wherein the cancer is selected from the group consisting of: head and neck cancer, ovarian cancer, gastric cancer, esophageal cancer, cervical cancer, prostate cancer, pancreatic cancer, estrogen receptors negative (ER-) breast cancer, progesterone receptors negative (PR-) breast cancer, HER2 negative (HER2-) triple negative breast cancer, glioblastoma, lung cancer, bladder cancer, melanoma, and kidney cancer, or

wherein the disease or condition involves neovascularization, optionally wherein the disease or condition involving neovascularization is cancer, or

wherein the disease or condition involves vascular inflammation.

14. The use of claim 13, wherein one or more additional therapeutic agents is to be further administered to the subject, optionally wherein:

the one or more additional therapeutic agents is formulated in a different pharmaceutical composition; or

the one or more additional therapeutic agents is to be administered prior to administration of the antibody-drug conjugate; or

the one or more additional therapeutic agents is to be administered after administration of the antibody-drug conjugate; or

the one or more additional therapeutic agents is to be administered contemporaneously with the antibody-drug conjugate.

15. A process for preparing an antibody-drug conjugate, the process comprising:

(A) reacting a nucleophilic or an electrophilic group on an antigen binding protein (Ab) which binds human Tissue Factor (TF) (SEQ ID NO:810) with a bifunctional linker, or with a first linker component of a bifunctional linker that comprises two or more linker components followed by sequential addition of the remaining linker component(s), to form an Ab-linker intermediate, and reacting the Ab-linker intermediate with the $-NH_2$ group of a compound of general Formula **I**:



Formula I

wherein:

X is *-C(O)NHCH($CH_2(R^2)$)-$^{+}$, wherein * and + represent the respective points of attachment as indicated in Formula **I**, or X is absent;

R^1 is selected from the group consisting of:



wherein # and % represent the respective points of attachment as indicated in Formula **I**; and R^2 is phenyl,

to provide the antibody drug conjugate; or

(B) reacting the -NH_2 group on the compound of general Formula **I** with a bifunctional linker, or with a first linker component of a bifunctional linker that comprises two or more linker components followed by sequential addition of the remaining linker component(s), to form a linker-toxin intermediate, and reacting the linker-toxin intermediate with a nucleophilic or an electrophilic group on an Ab which binds human TF (SEQ ID NO: 810) to provide the antibody-drug conjugate, wherein, in (A) or (B),

the Ab comprises a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3, wherein

i. the VH-CDR1 comprises the sequence of SEQ ID NO: 872, the VH-CDR2 comprises the sequence of SEQ ID NO: 873, the VH-CDR3 comprises the sequence of SEQ ID NO: 874, the VL-CDR1 comprises SEQ ID NO: 875, the VL-CDR2 comprises the sequence of SEQ ID

NO: 876, and the VL-CDR3 comprises the sequence of SEQ ID NO: 877,

ii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25A3,

iii. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25A,

iv. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25A5,

v. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25A5-T, or

vi. the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 are from the Ab designated 25G1;

resulting in the antibody-drug conjugate which comprises one or more moieties represented by Formula IV:



Formula IV

wherein:

X is *-C(O)NHCH($CH_2(R^2)$)-$^{+}$, wherein * and + represent the respective points of attachment as indicated in Formula IV, or X is absent;

L is a linker;

! represents the point of attachment of L to the Ab, where L is attached to the Ab through a covalent bond;

R^1 is selected from the group consisting of:



, and ,

wherein # and % represent the respective points of attachment as indicated in Formula IV; and

R^2 is phenyl.

16. The process according to claim 15, wherein:

the nucleophilic or electrophilic group on the Ab is a thiol or an amine, optionally further comprising contacting the Ab with a reducing agent to reduce one or more disulfide linkages in the Ab to provide the nucleophilic thiol group; and/or

wherein L is represented by:



Formula VII

wherein:

Z represents a functional group that binds to a target group of the Ab;

D represents the point of attachment to the amino group as indicated in Formula **I**;

Str is a stretcher;

AA_1 and AA_2 are each independently an amino acid, wherein AA_1-$[AA_2]_m$ forms a protease cleavage site;

X is a self-immolative group;

s is an integer selected from 1 and 0;

m is an integer selected from the group consisting of 1, 2, 3, and 4; and

o is an integer selected from 0, 1, and 2.

17. A kit comprising:

(i) the antibody-drug conjugate of any one of claims 1-10 or the pharmaceutical composition of claim 11 or 12; and

(ii) instructions for use.

18. The antibody-drug conjugate of any one of claims 0-10 or the pharmaceutical composition of claim 11 or 12 for use in therapy.